ABSTRACT
Most cancer drugs are today targeted to molecular alterations present in tumor cells regardless of the primary site or histology of the tumor. This has required the development of new paradigms and designs for clinical development. In this paper we review some clinical trial designs for conducting primary site independent clinical trials in oncology.
